drugset / Trial / NCT01409135
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.
Timeline
- Start
- 2011-07-11
- Primary completion
- 2015-04-27
- Completion
- 2015-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENFORTUMAB VEDOTIN | Monoclonal antibody | — | Intravenous |
| Subject | Enfortumab Vedotin | Other / unclassified | — | Intravenous |